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Abstract/Synopsis

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used as anti-inflammatory, anti-pyretic and analgesic agents in clinical medicine. The therapeutic effects of these drugs are due their action in inhibiting the enzyme, cyclooxygenase, which is responsible for the production of prostaglandins. However, the use of these drugs is often associated with significant adverse effects in the gastrointestinal tract, a circumstance that frequently results in poor patient compliance when used on a long-term basis. Several mechanisms have been shown to contribute to the pathogenesis of these effects in the small intestine. These include drug-induced inhibition of cyclooxygenase, oxidative stress, mitochondrial dysfunction and increased intestinal permeability. The studies described in this thesis have attempted to further elucidate mechanisms of damage involved, using indomethacin as a prototype NSAID. The studies also assessed the ability of curcumin and zinc to protect against indomethacin-induced small intestinal damage. These agents were chosen because they are well known to have anti-oxidants effects and have been shown to be cytoprotective in the gastrointestinal tract in other settings.  Cells in culture and an animal model were used for the studies done.  

The first study presented was designed to ascertain the role of cytosolic phospholipase A2 (cPLA2) in the pathogenesis of indomethacin-induced enteropathy. Phospholipase A2 (PLA2) is an enzyme that catalyzes the hydrolysis of the sn-2 fatty acyl bond of phospholipids to yield fatty acids and lysophospholipids.  It comprises both extracellular and intracellular forms. cPLA2 is an intracellular form that is found in the cytosol and is calcium-dependent. Previous work had shown evidence of activation of phospholipase A2 in the rat small intestine in response to indomethacin. It was thus hypothesized that the activation of this enzyme may be important in the development of damage in enterocytes. In order to test this, studies were carried out in Caco-2 cells, which are human small intestinal epithelial cells often used as models for enterocytes. The cells were incubated with indomethacin (500μM for 1 hour) with and without pre-treatment with methyl arachidonyl fluorophosphonate (MAFP), an inhibitor of cytosolic phospholipase A2 (20 μM for 30 minutes).

It was found that Caco-2 cells treated with indomethacin showed decreased viability and evidence of oxidative stress and morphological cell damage. Phospholipids were degraded in these cells, with increases in the levels of lysophospholipids and arachidonic acid, changes which were indicative of the action of phospholipase A2. There was no evidence of apoptosis in the cells in response to the drug, suggesting that cell death occurred as a result of non-apoptotic mechanisms. Pretreatment of the cells with MAFP attenuated the drug-induced effects seen.  These results showed that activation of phospholipase A2 appears to be an important event in the pathogenesis of indomethacin-induced damage in Caco-2 cells. As far as is known, this is the first report that implicates the involvement of this enzyme in NSAID-induced enteropathy. 

Indomethacin has been shown to produce oxidative stress and mitochondrial dysfunction in the rat small intestine. Curcumin (diferuloylmethane), a constituent of turmeric, is known to be an effective antioxidant. It is known to be cytoprotective in many experimental settings.  In view of this, the second part of the study was designed to assess the potential of curcumin as an agent to reduce indomethacin-induced oxidative stress and subsequent damage produced in the rat small intestine. 

Male albino rats were used for the animal studies done. They were pretreated with various doses of curcumin (20mg/kg, 40mg/kg and 80mg/kg) before administering indomethacin at 20 mg/kg. Various parameters of oxidative stress and the extent of small intestinal damage produced by indomethacin were assessed at 1 and 24 hours respectively after the drug.  These studies were carried both with and without pretreatment with curcumin. Macroscopic ulceration was found to occur in the small intestine in response to indomethacin, 24 hours after administration of the drug. The viability of enterocytes from indomethacin-treated animals was significantly lower than those from control animals, when assessed 1 hour after the drug. Drug-induced oxidative stress was also evident at the same time period, as seen by increases in the levels of malondialdehyde and protein carbonyl and in activities of pro-oxidant enzymes like myeloperoxidase and xanthine oxidase in the indomethacin-treated rats. Concomitant decreases were seen in the activities of the antioxidant enzymes, catalase and glutathione peroxidase, in these animals. Pretreatment with curcumin was found to ameliorate these drug-induced changes. It was, thus, concluded that curcumin appeared to hold promise as an agent that can potentially reduce NSAID-induced small intestinal damage.

The third part of the study attempted to study the mechanisms by which curcumin protected against small intestinal damage. Rats were pretreated with curcumin (40mg/kg by intra-peritoneal injection) before administration of indomethacin (20 mg/kg by gavage). One hour later, the small intestine was isolated and used for assessment of parameters of oxidative stress. Mitochondria, brush border membranes (BBM) and surfactant-like particles (SLP) were isolated from the tissue. Mitochondria were used for assessment of functional integrity, estimation of products of lipid peroxidation and lipid content.  BBM were used for estimation of products of lipid peroxidation and lipid content, while the SLP were used for measurement of lipid content. The results showed that oxidative stress and mitochondrial dysfunction occurred in the small intestine of indomethacin-treated rats. Pre-treatment with curcumin was found to ameliorate these drug-induced changes. Significant changes were seen in some of the lipids in the mitochondria, BBM and SLP in response to indomethacin. However, curcumin did not have any significant effect on these drug-induced changes. It was concluded that curcumin was able to protect against indomethacin-induced small intestinal damage by attenuating oxidative stress and mitochondrial dysfunction. It did not reverse drug-induced changes in the lipids of the intestinal mucosa. 

Alterations in the composition and function of the glycocalyx and brush border membranes of the rat small intestine have been shown to occur in response to indomethacin. The micronutrient, zinc, has been documented to have cytoprotective effects in the gastrointestinal tract.  The aim of the fourth part of the study was to evaluate the potential of zinc to reduce indomethacin-induced small intestinal damage. Rats were pre-treated with zinc sulphate (50mg/kg body weight) 2 hours before administration of indomethacin (20mg/kg body weight). The rats were sacrificed 24 hrs after the drug. Small intestinal mucosal damage and alterations in the content of lipids and sugars in the mucosa were assessed, at 24 hours and 1 hour respectively, after the drug. Bacterial counts in the intestinal lumen and the mucosa were determined at the 24 hour time period. Indomethacin was found to cause small intestinal ulceration. It also produced changes in the contents of lipids and sugars in the mucosa. This was associated with increases in the number of bacteria in the intestinal lumen and that adherent to the mucosa. Pre-treatment with zinc sulphate was found to attenuate all these effects. It was, thus, concluded that zinc was effective in protecting against indomethacin-induced small intestinal damage. 

The aim of the last part of this study was to further study biochemical mechanisms that may be involved in the pathogenesis of indomethacin-induced small intestinal damage. Various molecules, such as matrix metalloproteinases and nuclear factor kapp B (NF-KB), have been shown to be activated by oxidative stress. Studies were done to ascertain whether these molecules, and others downstream of them, were activated in response to indomethacin-induced oxidative stress in the small intestine. Attempts were also made to determine the mechanisms by which zinc acts as a cytoprotectant to reduce macroscopic damage produced by the drug. Zinc is known to be a potent inducer of metallothionein, which has marked anti-oxidant properties.  Metallothionein induced during zinc supplementation has been shown to scavenge hydroxyl radicals and thus prevent oxidative stress. Hence, metallothionein levels were determined. 

For this part of the study, rats were pre-treated with zinc sulphate (50mg/kg body weight) 2 hours before administration of indomethacin (20mg/kg body weight). The animals were sacrificed 1, 12 or 24 hrs after the dose of indomethacin. The activities of matrix metalloproteinase 2 and 9 (MMP-2 and -9) and tissue inhibitors of matrix metalloproteinases (TIMP) were determined. Evidence of nuclear factor kappa B (NFkB) activation was looked for. Expression levels of cyclooxygenase 2 (COX-2) and inducible nitric oxide (iNOS), both of which are downstream of NFkB, were also determined. In addition, the expression levels of metallothionein and heat shock protein 70 (HSP 70) were studied. The results obtained showed some evidence of NFkB activation and increased MMP activity in response to indomethacin. None of the other parameters measured were affected by the drug. Pretreatment with zinc was found to induce metallothionein to a significant extent and attenuate the drug-induced effects seen. It was, thus, concluded that the protective effects of zinc appeared to be mediated through induction of metallothionein, which is a potent anti-oxidant. 

In conclusion, the studies done present further insights into the mechanisms involved in the pathogenesis of indomethacin-induced small intestinal damage. Activation of cytosolic phospholipase A2 appears to be important in the process. There is some preliminary evidence that activation of NFkB and MMPs also occurs in response to indomethacin, possibly adding to the adverse effects of the drug on the tissue. Curcumin and zinc were found to be effective in attenuating many of the effects produced by the drug. Curcumin appeared to act by ameliorating drug-induced oxidative stress and mitochondrial dysfunction. The effect of zinc appeared to be mediated through its induction of metallothionein, a potent anti-oxidant. Hence, both curcumin and zinc hold potential as agents that can reduce indomethacin-induced small intestinal damage. 






